Abstract Details

Title Clinical Significance of Cerebrospinal Fluid IL-10 in Primary Central Nervous System Lymphoma: A Systematic Review With Meta-analysis

Topic Neuro-oncology

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-004

Objective To summarize the current evidence on the clinical significance of interleukin-10 (IL-10) in cerebrospinal fluid (CSF) on Primary central nervous system lymphoma (PCNSL).

Background PCNSL is a rare, aggressive lymphoma localized mainly in the brain, and spinal cord. IL-10 contributes to PCNSL pathogenesis by modulating immune activity and shaping the tumor microenvironment, positioning CSF IL-10 as a potential biomarker for diagnosis, disease monitoring and differentiation from other CNS tumors.

Design/Methods A systematic search of PubMed, Embase, Scopus, Web of Science, and Google Scholar up to August 2025 identified observational studies evaluating CSF IL-10 in PCNSL. Pooled sensitivity, specificity, and SROC area were calculated. Random-effects meta-analyses and sensitivity were conducted, with narrative synthesis applied when meta-analysis was not feasible. Subgroup analyses compared PCNSL with other CNS diseases, and study quality was evaluated using the Newcastle–Ottawa Scale.

Results Twelve studies (1205 participants) met inclusion criteria. Compared with a broad range of CNS diseases, IL-10 showed pooled sensitivity and specificity of 89.2% (95% CI, 52.1–98.4% and 48.6–98.6%, respectively) and AUC of 0.951 (95% CI, 0.872–0.998). Compared with other CNS tumors, sensitivity and specificity were 90.7% (95% CI, 46.0–99.1%) and 90.7% (95% CI, 32.3–99.5%), respectively, with an AUC of 0.962 (95% CI, 0.29–0.99). CSF IL-10 levels were significantly higher in PCNSL than systemic non-Hodgkin lymphoma (SMD 1.89; 2 studies; 111 participants; 95% CI, 1.03–2.74; I² = 69.3%) and in PCNSL with CSF involvement (SMD 2.35; 3 studies; 472 participants; 95% CI, 0.82–3.88; I² = 94.9%). All studies demonstrated low risk of bias.

Conclusions

CSF IL-10 exhibits high diagnostic accuracy for PCNSL. Nevertheless, the wide confidence intervals reflect heterogeneity across studies, likely due to differences in cut-off values, study populations, and comparator conditions. Despite this variability, the consistently elevated IL-10 levels observed in PCNSL are promising, supporting its potential as a reliable biomarker for diagnosis and disease monitoring.

Authors/Disclosures
Ivan Alegre-Cordero PRESENTER	Mr. Alegre-Cordero has nothing to disclose.
Gerardo M. Luna-Peralta	Mr. Luna-Peralta has nothing to disclose.
Arturo Jhonny Ruiz Yaringano	Mr. Ruiz Yaringano has nothing to disclose.
Bryan E. Rudas Sulca, Medical student	Mr. Rudas Sulca has nothing to disclose.
Freddy F. Arcos Rivera	Mr. Arcos Rivera has nothing to disclose.
GABRIEL ELGUERA ROJAS, Sr., Medical Student	Mr. ELGUERA ROJAS has nothing to disclose.
Miguel F. Cabanillas Lazo	Mr. Cabanillas Lazo has nothing to disclose.
Carlos Rodrigo Q. Vicuña	Mr. Vicuña has nothing to disclose.

��ɫ��

��ɫ��